Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
FluoroPharma Medical's 5-Year RORE % for the quarter that ended in Dec. 2016 was 0.00%.
The industry rank for FluoroPharma Medical's 5-Year RORE % or its related term are showing as below:
FPMI's 5-Year RORE % is not ranked *
in the Biotechnology industry.
Industry Median: -10.555 * Ranked among companies with meaningful 5-Year RORE % only.
FluoroPharma Medical (OTCPK:FPMI) 5-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 5-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
FluoroPharma Medical 5-Year RORE % Related Terms
FluoroPharma Medical 5-Year RORE % Historical Data
* Premium members only.
The historical data trend for FluoroPharma Medical's 5-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FPMI vs HSTC, OBMPD, GOVX: 5-Year RORE % Comparison
For the Biotechnology subindustry, FluoroPharma Medical's 5-Year RORE %, along with its competitors' market caps and 5-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
FluoroPharma Medical 5-Year RORE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, FluoroPharma Medical's 5-Year RORE % distribution charts can be found below:
* The bar in red indicates where FluoroPharma Medical's 5-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 5-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2016 and 5-year before.
FluoroPharma Medical (FPMI) has a 5-Year RORE % of 0.00 as of Dec. 2016. 5-Year RORE % shows how much a company earns by reinvesting its retained earnings in 5-year. View historical data on FluoroPharma Medical and its competitors.
Is FluoroPharma Medical's 5-Year RORE % too high?
FluoroPharma Medical's current 5-Year RORE % is 0.00.
How does FluoroPharma Medical's 5-Year RORE % compare to HSTC and OBMPD?
FluoroPharma Medical's 5-Year RORE % of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year RORE % for a Biotechnology company?
A good 5-Year RORE % depends on the Biotechnology industry context. However, 5-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year RORE % mean?
A high 5-Year RORE % can signal that a stock is expensive relative to its fundamentals. 5-Year RORE % shows how much a company earns by reinvesting its retained earnings in 5-year. View historical data on FluoroPharma Medical and its competitors. FluoroPharma Medical's current 5-Year RORE % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is FluoroPharma Medical stock overvalued right now?
FluoroPharma Medical (FPMI) has a current 5-Year RORE % of 0.00. The current 5-Year RORE % is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year RORE % calculated?
5-Year RORE % is calculated from a company's financial statements. For FluoroPharma Medical (FPMI), the current 5-Year RORE % is 0.00 as of Dec. 2016. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
FluoroPharma Medical Inc is a us-based biopharmaceutical company. It specializes in developing and commercializing molecular imaging pharmaceuticals with initial applications in the area of cardiology. The company focuses on the development of novel cardiovascular imaging agents which detect and assess acute and chronic forms of coronary artery disease (CAD). The company's clinical-stage molecular imaging pharmaceutical product candidates are 18-F TPP (BFPET) and 18-F FCPHA (CardioPET). The 18-F TPP is designed for use in stress-testing for patients with proven CAD whereas 18-F FCPHA is a molecular imaging agent which is designed to assess myocardial blood flow and metabolism in patients with CAD. The company operates in a single segment being Biopharmaceutical research and development.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FPMI has been successfully added to your 
